PubMed Health⌕ Search

Biomedical subjects

L Galantino

Publications and source records attributed to L Galantino.

4 recordsLinked to original sources
PubMed1994

[Survival of autologous indium-111-oxine-labeled blood platelets in patients with ischemic diseases].

Platelet half-life was assessed with autologous 111In-marked platelets in fourteen subjects, four women and ten men, who previously had suffered vascular accidents (myocardial infarction, TIA, stroke or peripheral obstructive arterial disease). Results, compared to findings in low risk subjects showed a statistically significant correlation of platelet half-life to certain pathologies (TIA, stroke) as well as to habits (tobacco, alcohol) and biological variables (age, sex). By and large, data were analogous to those of the current scientific literature in so far as certain factors shorten platelet half-life. A correlation was also found between platelet half-life and time elapsed since the pathological event. Liver sequestration evaluated by total body scintigraphy showed high levels in one case each with a history of stroke, a history of TIA, and a history of peripheral arterial disease, and splenic sequestration in only one case with a history of stroke.

Adult↗
PubMed1989

[Clinical and hemodynamic effects of medium-term ketanserin treatment in 2 compared groups of obese and non-obese hypertensive patients].

We evaluated systemic and central hemodynamics in 10 lean hypertensives and in 10 obese hypertensives (WHO stage I-II) after 8 weeks treatment regimen with a serotoninergic antagonist such as ketanserin. At the beginning and at the end of the study, body weight, BMI, blood pressure and heart rate were measured and a first pass radionuclide angiocardiography was performed to determine cardiac output, cardiac index and ejection fraction of left ventricle. Total peripheral resistances were also calculated. In both hypertensive groups ketanserin significantly reduced diastolic (p less than 0.05) and mean (p less than 0.005) blood pressure. No significant change in systolic blood pressure, cardiac output, cardiac index and ejection fraction of left ventricle has been observed in lean and obese hypertensives. Total peripheral resistance values significantly (p less than 0.05) decreased in lean hypertensives; in obese hypertensives total peripheral resistance moderately reduced. Our results indicated that monotherapy with ketanserin is effective in treating mild to moderate hypertension both in lean and in obese hypertensives and did not interfere with left ventricular performance. At last the effectiveness of ketanserin treatment appears moderately higher in lean than in obese hypertensives.

Adult↗
PubMedDate not supplied

Clinical and haemodynamic effects of ketanserin in lean and obese hypertensive patients.

Systemic and central haemodynamics were evaluated in 10 lean and 10 obese hypertensive patients (World Health Organization stage I-II) after treatment for 8 weeks with a serotoninergic antagonist, such as ketanserin. Blood pressure and heart rate were recorded and first-pass radionuclide angiocardiography was performed to determine cardiac output, cardiac index and ejection fraction of the left ventricle; total peripheral resistance was also calculated. In both obese and lean patients, ketanserin significantly reduced diastolic (P less than 0.05) and mean (P less than 0.005) blood pressure but no significant changes in systolic blood pressure, cardiac output, cardiac index and ejection fraction were observed in lean and obese hypertensive patients. Total peripheral resistance was significantly (P less than 0.05) reduced in lean patients but in obese hypertensives it was only moderately reduced. It is concluded that monotherapy with ketanserin is effective in treating mild to moderate hypertension in both lean and obese hypertensive patients, without interfering with left ventricular performance.

Adult↗